カテゴリー： 世界, 医療/バイオ, Transparency Market Research

世界の間葉系幹細胞市場2023-2031：製品・サービス別（製品、サービス）、分離源別（骨髄、脂肪、臍帯血、末梢血、歯髄、その他）

【英語タイトル】Mesenchymal Stem Cells Market (Products & Services: Product and Services; Source of Isolation: Bone Marrow, Adipose, Cord Blood, Peripheral Blood, Dental Pulp, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが出版した調査資料（TMR23JUL264）・商品コード：TMR23JUL264
・発行会社（調査会社）：Transparency Market Research
・発行日：2023年4月
・ページ数：237
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Transparency Market Research社の市場調査では、世界の間葉系幹細胞市場規模が2023年の32億ドルから2031年には101億ドルに達し、予想期間中の年平均成長率は12.7％を記録すると予想されています。本書では、間葉系幹細胞の世界市場ついて広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、製品・サービス別（製品、サービス）分析、種類別（自家、同種）分析、分離源別（骨髄、歯髄、その他）分析、疾患別（筋骨格系疾患、心血管疾患、神経疾患、自己免疫疾患、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを整理しました。また、本書には、Thermo Fisher Scientific, Inc.、Cytiva (Danaher Corporation)、FUJIFILM Irvine Scientific (FUJIFILM Corporation)、Merck KGaA、Lonza Group Ltd.、STEMCELL Technologies, Inc.、Takara Bio, Inc.、Sartorius AG、Miltenyi Biotec GmbH and、PromoCell GmbHなどの企業情報が記載されています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要洞察
・世界の間葉系幹細胞市場規模：製品・サービス別
- 製品の市場規模
- サービスの市場規模
・世界の間葉系幹細胞市場規模：種類別
- 自家間葉系幹細胞の市場規模
- 同種間葉系幹細胞の市場規模
・世界の間葉系幹細胞市場規模：分離源別
- 骨髄における市場規模
- 歯髄における市場規模
- その他分離源における市場規模
・世界の間葉系幹細胞市場規模：疾患別
- 筋骨格系疾患における市場規模
- 心血管疾患における市場規模
- 神経疾患における市場規模
- 自己免疫疾患における市場規模
- その他疾患における市場規模
・世界の間葉系幹細胞市場規模：地域別
- 北米の間葉系幹細胞市場規模
- ヨーロッパの間葉系幹細胞市場規模
- アジア太平洋の間葉系幹細胞市場規模
- 中南米の間葉系幹細胞市場規模
- 中東・アフリカの間葉系幹細胞市場規模
・競争状況

Mesenchymal Stem Cells Market – Scope of Report
TMR’s report on the global Mesenchymal Stem Cells Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Mesenchymal Stem Cells Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Mesenchymal Stem Cells Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.

The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Mesenchymal Stem Cells Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Mesenchymal Stem Cells Market profiled in this report.

Key Questions Answered in Global Mesenchymal Stem Cells Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Mesenchymal Stem Cells Market – Research Objectives and Research Approach
The comprehensive report on the global Mesenchymal Stem Cells Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Mesenchymal Stem Cells Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mesenchymal Stem Cells Market
4. Market Overview
    4.1. Introduction
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Mesenchymal Stem Cells Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. List Of Major Research Institutes Involved In Mesenchymal Stem Cells Studies
    5.3. Mesenchymal Stem Cells: Current Trends and Future Prospects in a Variety of Disease Conditions
    5.4. Regulatory Scenario by Region/globally
    5.5. COVID-19 Pandemic Impact on Industry
6. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Products & Services
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Products & Services, 2017–2031
        6.3.1. Product
            6.3.1.1. Workflow Type
            6.3.1.2. Product Type
        6.3.2. Services
    6.4. Market Attractiveness Analysis, by Products & Services
7. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Type
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Type, 2017–2031
        7.3.1. Autologous
        7.3.2. Allogenic
    7.4. Market Attractiveness Analysis, by Type
8. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Source of Isolation
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Source of Isolation, 2017–2031
        8.3.1. Bone Marrow
            8.3.1.1. Adipose
            8.3.1.2. Cord Blood
            8.3.1.3. Peripheral Blood
        8.3.2. Dental Pulp
        8.3.3. Others (lung tissue, umbilical cord tissue, etc.)
    8.4. Market Attractiveness Analysis, by Source of Isolation
9. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Indication
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Indication, 2017–2031
        9.3.1. Musculoskeletal Diseases
        9.3.2. Cardiovascular Diseases
        9.3.3. Neuro Disorders
        9.3.4. Autoimmune Diseases
        9.3.5. Cancer
        9.3.6. GvHD
        9.3.7. Pulmonary Diseases
        9.3.8. Others
    9.4. Market Attractiveness Analysis, by Indication
10. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Mesenchymal Stem Cells Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Products & Services, 2017–2031
        11.2.1. Product
            11.2.1.1. Workflow Type
            11.2.1.2. Product Type
        11.2.2. Services
    11.3. Market Value Forecast, by Type, 2017–2031
        11.3.1. Autologous
        11.3.2. Allogenic
    11.4. Market Value Forecast, by Source of Isolation, 2017–2031
        11.4.1. Bone Marrow
            11.4.1.1. Adipose
            11.4.1.2. Cord Blood
            11.4.1.3. Peripheral Blood
        11.4.2. Dental Pulp
        11.4.3. Others (lung tissue, umbilical cord tissue, etc.)
    11.5. Market Value Forecast, by Indication , 2017–2031
        11.5.1. Musculoskeletal Diseases
        11.5.2. Cardiovascular Diseases
        11.5.3. Neuro Disorders
        11.5.4. Autoimmune Diseases
        11.5.5. Cancer
        11.5.6. GvHD
        11.5.7. Pulmonary Diseases
        11.5.8. Others
    11.6. Market Value Forecast, by Country, 2017–2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Product
        11.7.2. By Type
        11.7.3. By Source of Isolation
        11.7.4. By Indication
        11.7.5. By Country
12. Europe Mesenchymal Stem Cells Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Products & Services, 2017–2031
        12.2.1. Product
            12.2.1.1. Workflow Type
            12.2.1.2. Product Type
        12.2.2. Services
    12.3. Market Value Forecast, by Type, 2017–2031
        12.3.1. Autologous
        12.3.2. Allogenic
    12.4. Market Value Forecast, by Source of Isolation, 2017–2031
        12.4.1. Bone Marrow
            12.4.1.1. Adipose
            12.4.1.2. Cord Blood
            12.4.1.3. Peripheral Blood
        12.4.2. Dental Pulp
        12.4.3. Others (lung tissue, umbilical cord tissue, etc.)
    12.5. Market Value Forecast, by Indication , 2017–2031
        12.5.1. Musculoskeletal Diseases
        12.5.2. Cardiovascular Diseases
        12.5.3. Neuro Disorders
        12.5.4. Autoimmune Diseases
        12.5.5. Cancer
        12.5.6. GvHD
        12.5.7. Pulmonary Diseases
        12.5.8. Others
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Product
        12.7.2. By Type
        12.7.3. By Source of Isolation
        12.7.4. By Indication
        12.7.5. By Country/Sub-region
13. Asia Pacific Mesenchymal Stem Cells Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Products & Services, 2017–2031
        13.2.1. Product
            13.2.1.1. Workflow Type
            13.2.1.2. Product Type
        13.2.2. Services
    13.3. Market Value Forecast, by Type, 2017–2031
        13.3.1. Autologous
        13.3.2. Allogenic
    13.4. Market Value Forecast, by Source of Isolation, 2017–2031
        13.4.1. Bone Marrow
            13.4.1.1. Adipose
            13.4.1.2. Cord Blood
            13.4.1.3. Peripheral Blood
        13.4.2. Dental Pulp
        13.4.3. Others (lung tissue, umbilical cord tissue, etc.)
    13.5. Market Value Forecast, by Indication , 2017–2031
        13.5.1. Musculoskeletal Diseases
        13.5.2. Cardiovascular Diseases
        13.5.3. Neuro Disorders
        13.5.4. Autoimmune Diseases
        13.5.5. Cancer
        13.5.6. GvHD
        13.5.7. Pulmonary Diseases
        13.5.8. Others
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. South Korea
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Product
        13.7.2. By Type
        13.7.3. By Source of Isolation
        13.7.4. By Indication
        13.7.5. By Country/Sub-region
14. Latin America Mesenchymal Stem Cells Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Products & Services, 2017–2031
        14.2.1. Product
            14.2.1.1. Workflow Type
            14.2.1.2. Product Type
        14.2.2. Services
    14.3. Market Value Forecast, by Type, 2017–2031
        14.3.1. Autologous
        14.3.2. Allogenic
    14.4. Market Value Forecast, by Source of Isolation, 2017–2031
        14.4.1. Bone Marrow
            14.4.1.1. Adipose
            14.4.1.2. Cord Blood
            14.4.1.3. Peripheral Blood
        14.4.2. Dental Pulp
        14.4.3. Others (lung tissue, umbilical cord tissue, etc.)
    14.5. Market Value Forecast, by Indication , 2017–2031
        14.5.1. Musculoskeletal Diseases
        14.5.2. Cardiovascular Diseases
        14.5.3. Neuro Disorders
        14.5.4. Autoimmune Diseases
        14.5.5. Cancer
        14.5.6. GvHD
        14.5.7. Pulmonary Diseases
        14.5.8. Others
    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Product
        14.7.2. By Type
        14.7.3. By Source of Isolation
        14.7.4. By Indication
        14.7.5. By Country/Sub-region
15. Middle East & Africa Mesenchymal Stem Cells Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Products & Services, 2017–2031
        15.2.1. Product
            15.2.1.1. Workflow Type
            15.2.1.2. Product Type
        15.2.2. Services
    15.3. Market Value Forecast, by Type, 2017–2031
        15.3.1. Autologous
        15.3.2. Allogenic
    15.4. Market Value Forecast, by Source of Isolation, 2017–2031
        15.4.1. Bone Marrow
            15.4.1.1. Adipose
            15.4.1.2. Cord Blood
            15.4.1.3. Peripheral Blood
        15.4.2. Dental Pulp
        15.4.3. Others (lung tissue, umbilical cord tissue, etc.)
    15.5. Market Value Forecast, by Indication, 2017–2031
        15.5.1. Musculoskeletal Diseases
        15.5.2. Cardiovascular Diseases
        15.5.3. Neuro Disorders
        15.5.4. Autoimmune Diseases
        15.5.5. Cancer
        15.5.6. GvHD
        15.5.7. Pulmonary Diseases
        15.5.8. Others
    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Product
        15.7.2. By Type
        15.7.3. By Source of Isolation
        15.7.4. By Indication
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company, 2021
    16.3. Company Profiles
        16.3.1. Thermo Fisher Scientific, Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Cytiva (Danaher Corporation)
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. FUJIFILM Irvine Scientific (FUJIFILM Corporation)
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Merck KGaA
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Lonza Group Ltd.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. STEMCELL Technologies, Inc.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Takara Bio, Inc.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Sartorius AG
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Miltenyi Biotec GmbH
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. PromoCell GmbH
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

Table 02: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

Table 03: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

Table 04: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2032

Table 05: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

Table 06: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Region, 2017–2032

Table 07: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country, 2017–2032

Table 08: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

Table 09: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

Table 10: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

Table 11: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

Table 12: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

Table 13: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

Table 14: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

Table 15: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

Table 16: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

Table 17: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

Table 18: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

Table 19: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

Table 20: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

Table 21: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

Table 22: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

Table 23: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

Table 24: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

Table 25: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

Table 26: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

Table 27: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

Table 28: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

Table 29: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

Table 30: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

Table 31: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

Table 32: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

Table 33: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

Table 34: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

Table 35: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

Table 36: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

★調査レポート[世界の間葉系幹細胞市場2023-2031：製品・サービス別（製品、サービス）、分離源別（骨髄、脂肪、臍帯血、末梢血、歯髄、その他）] (コード：TMR23JUL264)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の間葉系幹細胞市場2023-2031：製品・サービス別（製品、サービス）、分離源別（骨髄、脂肪、臍帯血、末梢血、歯髄、その他）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の間葉系幹細胞市場2023-2030：製品・サービス別、ワークフロー別、種類別、隔離源別、疾患別、用途別、地域別
  • 世界の電力用アンシラリーサービス市場2023-2031：サービス別（周波数制御アンシラリーサービス、ネットワーク制御アンシラリーサービス、その他）
  • 世界の細胞分析市場2023-2031：製品&サービス別（試薬&消耗品、器具、アクセサリ、ソフトウェア、サービス）、技術別（フローサイトメトリー、PCR、細胞マイクロアレイ、顕微鏡検査、分光測光法、ハイコンテントスクリーニング、その他技術）、工程別（細胞同定、細胞生存率、細胞シグナル伝達経路、細胞増殖、細胞計数&品質管理、細胞相互作用、細胞構造研究、標的同定&検証、単一細胞分析）、エンドユーザー別（バイオ医薬品&バイオテクノロジー企業、病院&臨床試験所、学術&研究機関、その他）、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）
  • 世界の産業用DeNOxシステム・サービス市場2023-2031：サービス別（新規設置、アフターマーケットサービス）、種類別（選択的触媒還元、選択的無触媒還元）
  • 世界の生細胞イメージング市場2022-2029：製品＆サービス別（機器、消耗品、ソフトウェア、サービス）、用途別、エンドユーザー別、地域別
  • 世界の生細胞イメージング市場2022-2029：製品＆サービス別（機器、消耗品、ソフトウェア、サービス）、用途別、エンドユーザー別、地域別
  • 世界の自然再生サービス市場2022-2031：種類別（小川、湿地、土地、その他）、サービス別（モニタリング、計画、設計・エンジニアリング、コンサルティング、物理的修復、用地取得、その他）

    • ◆H&Iグローバルリサーチのお客様（例）◆